Additionally, it has been documented that upregulation of miR-29a enhances sensitivity of DDP in CD133 positive (CD133+) cells, a type of CSCs in GBM, and reverses poor prognosis in vitro and in vivo [144]. Here, PROM1 is linked to glioblastoma.